The new crown medicine Qianjin vine, is it sickle or leek?

Home > Health

The new crown medicine Qianjin vine, is it sickle or leek?

2022-05-15 18:13:02 24 ℃

Originally, I planned to take a break today and glanced at the background to leave a message. Many people are very concerned about the concept of "Qianjin Fujin", and there are even small watches. Yes It is Dali Pharmaceutical, and then said that Buchang Pharmaceutical is the most authentic, and it is said that Cuiwei shares participated in the shares, and there are 30 cm clean and white. The ability of the great gods to excavate all the great gods is really superb, so let's summarize it.

The attraction caused by Qianjin Fujin is related to a message

On May 10, the official of Beijing University of Chemical Technology released an article: Professor Tong Yigang's team found that Qianjinjotu obtained a national invention patent. Beijing University of Chemical Technology also pointed out in Guanwei: American scholars have published papers in Science and confirmed that the data of Qianjinjotin is better than Redsovir and Palowder. In an interview, Tong Yigang explained: "In general, if there are 15,393 viruses, the number of viruses will be only one after using 10um thousands of golden vines." The company will contact the FDA of the United States. It is expected to launch the clinical trial of the new crown of Qianjinjotin in the second half of this year. The approval of the new patent may mean that the new crown of Qianjinjotin treatment will become a reality.

The natural source of Qianjinjo Su is the Qianjin vine plant that prevents himself. In 1934, Professor Kondo Toshiro, a University of Pharmacist at Tokyo, was separated and extracted from Stephania Cepharantha Hayata, and his English name " CEPHARANTHINE (CEP) "is also from Cepharantha.

This medicine has been used in clinical practice for decades. It was first used for anti -tuberculosis treatment. The effect was very average, but the white blood cells of many patients were found in the treatment process. Treatment of leukocyte reduction, especially in the process of anti -tumor (such as chemotherapy) in the process of anti -tumor.

Before the new crown epidemic, some cytology studies have shown that Qianjinvin has anti-inflammatory, antiviral and antiviral effects. For example, some studies have found that Qianjinjotin can be on HCOV-OC43 (a coronary virus that usually causes colds) and SARS Virus has antiviral effects (research from the Chinese Academy of Sciences in 2005). Therefore, after the outbreak of the new crown epidemic, in the case where the effective drugs of the new crown virus were very limited, Qianjinjotu also entered large drug screening with many other old medicines. Researchers from various countries not only hope to develop new drugs, but also hope that a lot of old medicines can find drugs that can effectively fight the new coronary virus.

The earliest research on the Qianjin Tengshu against the new coronal virus, from the team of Professor Tong Yigang from Beijing University of Chemical Technology. Researchers used a pangolin crown virus (GX_P2V) as a virus model to screen 2406 drugs that have been approved for marketing, and the cell lines used were Vero E6 cells.

Although not the new coronary virus, the S protein of GX_P2V has 92.2%of the amino acid consistency of the new coronary virus S protein in Wuhan at the time, and also uses ACE2 as the receptor of the invasive cell. Therefore Study model.

Among more than 2,000 drugs, researchers have screened three most promising new anti -new coronary virus potential drugs, including Qianjin vine, serachin, and methalin hydrochloride. Fujimin, its antiviral activity EC50 (semi -inhibitory concentration, the lower the number, the stronger the activity) is 0.98 μmol/L. Among the cells treated with 10 μmol/L thousand golden vine 15393 times.

At present, four companies in China have relatively mature production processes and production lines.

1. Shenyang Guancheng Pharmaceutical Co., Ltd.

2. Yunnan Baiyao Group Wenshan Qihua Co., Ltd.

3. Yunnan Biotechnology Corber Industry Co., Ltd.

4. Yunnan Baiyao Group Dali Pharmaceutical Co., Ltd.) can be produced.

Please note that the Yunnan Baiyao Group Dali Pharmaceutical Co., Ltd. and the listed company Dali Pharmaceutical are not a company. The full name of the listed company Dali Pharmaceutical Co., Ltd.

What are the Qianjinjotu listed companies?

1. Yunnan Baiyao Company is a large -scale medical and healthy pharmaceutical company focusing on pharmaceutical research and development, pharmaceutical manufacturing, daily chemical care, health care, medicinal materials trade, wholesale retail, and pharmaceutical logistics. Adhering to the concept of "inheritance of no mud and innovation", the company has practiced internal skills with the spirit of craftsmen, has accumulated a lot of hair, excelsed and dedicated to the market with quality and reputation.

2. Building Pharmaceutical: The company has a invention patent for the preparation method of Qianjotin hydrochloride.

The company's conventional concepts include: influenza, generic drug consistency evaluation, S & P Dow Jones A shares, MSCI concepts, new crown therapy, biochemical vaccine, medical device concepts, medical beauty concepts, banks participating in banks, and shares. The main business of the stepped pharmaceutical is the R & D, production and sales of Chinese medicine.

3. Neptune Biological Company invented a thousand golden vines slowly release agent. This preparation contains the complementary materials that can be accepted in the pharmaceutical and pharmaceuticals. The weight ratio of the two is 2 ~ 8: 1 to 7. The slow -release preparations include osteogenesis mitter -release preparations, membrane -controlled slow -release preparations, osmotic pump -type slow -release preparations, and mitigation preparations made into microcapsules, microfin, small pills before. The Qianjin vine sustained -release preparation provided by the present invention can extend the time of drug action, reduce the number of taking, reduce the side effects of the drug, and improve the compliance of medication, and provide patients with a safer, effective and reliable drug treatment method for patients. 4. Bai Tu shares indirectly invested in Yunnan Biofeng Corber Industry Co., Ltd. through Gaosajia Ruikang.

5. Aladdin scientific research preparation.

6. The official website of Yoning Victoria is selling thousands of golden vines.

7. Cuiwei shareholders are indirectly held biological valley shares.

8. Dongcheng Pharmaceutical's subsidiary has the method of preparing a thousand golden vines capsules.

9. Biological Valley has a mature production process and route of Qianjin vine.

At present, the individual stocks that can be collected are basically here. What other supplements can be seen in the message area.

on the other hand

The technical and invention patent of "Qianjin Fujin" belongs to Beijing University of Chemical Technology! Not other companies! In other words, even if other companies have "Qianjin Tengshu", or "Qianjin Fujin" produce a patent, it is not the "Qianjin vines" for treating the new crown virus! Some netizens also turned out the planting of "Qian Jin Teng". In fact, "Qian Jin Teng" is available in many places!

The earliest research on the Qianjin Tengshu against the new coronal virus, from the team of Professor Tong Yigang from Beijing University of Chemical Technology. Researchers used a pangolin crown virus (GX_P2V) as a virus model to screen 2406 drugs that have been approved for marketing, and the cell lines used were Vero E6 cells.

Although not the new coronary virus, the S protein of GX_P2V has 92.2%of the amino acid consistency of the new coronary virus S protein in Wuhan at the time, and also uses ACE2 as the receptor of the invasive cell. Therefore Study model.

Among more than 2,000 drugs, researchers have screened three most promising new anti -new coronary virus potential drugs, including Qianjin vine, serachin, and methalin hydrochloride. Fujimin, its antiviral activity EC50 (semi -inhibitory concentration, the lower the number, the stronger the activity) is 0.98 μmol/L. Among the cells treated with 10 μmol/L thousand golden vine 15393 times.

However, the limitations of the above research are that it is not a new coronal virus. If further demonstration is needed, the new crown virus must be used for testing.

In 2021, researchers at the Institute of Infection of Japan published a study, indicating that Qianjinjotu and Nelfinavir (used to treat HIV) jointly used the potential of anti -new coronal virus. It is Veroe6/TMPRSS2 cells.

The principles of these two drugs anti -new coronal virus are that Qianjin vine can be combined with the S protein of the new coronary virus to interfere with its invasion of host cells, while Nivisov inhibits virus replication through protease. According to the prediction of virus dynamic data, the two drugs can not detect the virus level 6.15 days in advance than the non -treatment control group, 1.23 days in advance than the use of Nikonovy alone, which means that the joint use or simply use Naisa Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Na Naa Wei can shorten infection time. Researchers used RemDesivir's reference. In vitro experiments showed that the IC50 of Qianjinjotin was even lower than RemDesivir (0.35um vs 1.58um), showing a powerful antiviral activity.

However, the study also found that according to the lung concentration of the two drugs, the antiviral effect of the oral vanartin is limited (because the concentration in the body is very low), and the intravenous administration can achieve higher drug concentration, especially in the lungs. Therefore, the researchers believe that the co -administration of Nepai Nave's mouth and Chibin vine intravenous vein may achieve a better anti -new coronal virus effect.

Of course, the above studies are still in vitro experiments, not clinical trials. In vitro experiments, the metabolism of the in vitro experiments and the real difference between the human body, including the drug concentration of oral vanartin, the removal speed of the new coronary virus, and the removal of the new coronary virus, and the speed of the new coronary virus, and the removal of the new coronary virus, and the removal of the new coronary virus, and the speed of the new coronary virus, and the speed of the new coronary virus, and the speed of the new coronary virus, and the speed of the new coronary virus, and the speed of the new coronary virus, and the speed of the new coronary virus, and the speed of the new coronary virus, and the speed of the new coronary virus, and the speed of the new coronary virus, and the speed of the new coronary virus, and the speed of the new crown virus and the speed of the new coronary virus. The degree of relief of the symptoms requires strict clinical trials to judge.

Another more important point is security. Qianjinjotu has been approved for more than 70 years, but it has multiple mechanisms in the body. For example, how will the blood image change after use for those who are infected with new crowns, which requires strict monitoring.

Therefore, if a medicine was found in early 2020, but after more than two years, it still did not really enter the clinical trial stage, then there are usually two possibilities:

-The first possibility is that there are problems with the approval mechanism of clinical trials;

-The second possibility, this medicine itself has limitations.

The limitations of drugs are not unsolvable. Some oral drugs can achieve significant improvement through transformation. For example, using capsules, adjusting the frequency of medication, or adding some auxiliary drugs can change their pharmacokinetics. Only after a large number of experiments and improvement improvementIn order to make a drug achieve the best clinical effect.The IC50 of Qianjinjo in vitro experiments is very low, indicating that it has strong antiviral potential, but how it is distributed in the body is a very important issue.This requires us to conduct more in -depth research on these candidate antiviral drugs, and use rigorous clinical trials to prove its safety and effectiveness to find effective weapons against the new coronary virus as soon as possible.

This is the reason why the most explosive themes in Friday and even weekends are not rushing to tweet, but A shares, often you know, I wo n’t say much. The benevolent sees the benevolent, the wise sees wisdom, there is no right or wrong, only success or failure!